BioAtla, Inc. Common Stock
BCABStock
$3.99−79.65%52W
Market Cap$7.07M
P/E—
Div yield—
Beta0.76
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-89.81%
Price vs S&P 500 (4W)12.55%
VGM Score21.31
Market Capitalization$7.07M
Analyst Recommendations
Apr 2026
May 2026
Jun 2026
Jul 2026
4.29
4.29
4.29
4.29
Industry Peers — Biological Products(180)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
BCABBioAtla, Inc. Common Stock | — | F | D | $3.99 |
| AMGNAmgen Inc | C | C | C | $371.58 |
| GILDGilead Sciences Inc | C | B | C | $136.30 |
| ARGXargenx SE American Depositary Shares | D | A | B | $857.97 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $179.18 |
| BIIBBiogen Inc. Common Stock | B | D | B | $208.92 |
| BNTXBioNTech SE American Depositary Share | C | C | C | $91.56 |
| MRNAModerna, Inc. Common Stock | D | B | B | $63.15 |
| NBIXNeurocrine Biosciences Inc | C | B | B | $171.55 |
| EXELExelixis Inc | C | B | B | $55.68 |
| TECHBio-Techne Corp. | D | C | B | $71.77 |
About
BioAtla Inc is a clinical-stage biopharmaceutical company developing antibody-based therapeutics for solid tumor cancers. The company's pipeline includes multiple programs featuring designed antibodies and bispecific antibodies, with lead candidates mecbotamab vedotin, ozuriftamab vedotin, and evalstotug in development, along with a Phase 1 trial for BA3182, a bispecific antibody targeting EpCAM and CD3. Its focus on precision-engineered antibodies aims to address unmet needs in oncology with potentially improved specificity and tolerability compared to conventional approaches.